How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT
Top Cited Papers
Open Access
- 17 December 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (24) , 6283-6290
Abstract
We performed a study to find out how advances in modern medicine have improved the mortality risk of allogeneic stem cell transplantation. We analyzed major transplantation outcome parameters in adult patients on the European Society for Blood and Marrow Transplantation (EBMT) registry who had hematologic malignancies and had received transplants from matched sibling donors. We performed multivariate analyses using the Cox proportional-hazards model including known risk factors for nonrelapse mortality and a matched-pairs analysis. We identified 38 800 patients who fulfilled the inclusion criteria. Considerable changes in patient characteristics have occurred in the past decades, such as older age, different underlying diseases, and a higher proportion of patients with advanced disease. Major reasons for transplantation-related death in the 1980s were infectious complications and graft-versus-host disease. Nonrelapse mortality, measured at 1 year after transplantation, has decreased over time: 29.7% from 1980 through 1989, 24.4% from 1990 through 1999, 14.8% from 2000 through 2009, and 12.2% from 2010 through 2016. On multivariate analysis, the year of transplantation was associated with reduced nonrelapse mortality (P < .0001; hazard ratio [HR] [95% confidence interval (CI)], 0.8 [0.79-0.82], for 5-year intervals) and decreased overall mortality (P < .0001; HR [95% CI], 0.87 [0.86-0.88]. In the matched-pairs analysis of 3718 patients in each group, nonrelapse mortality at 1 year was 24.4% in the 1990s and 9.5% from 2013 through 2016 (P < .0001; HR [95% CI], 0.39 [0.34-0.43]). Transplantation-related mortality has decreased significantly in the past 40 years. These favorable data facilitate evidence-based treatment decisions on transplantation indications in the context of the availability of novel immunotherapies.Keywords
This publication has 26 references indexed in Scilit:
- Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMTHaematologica, 2015
- Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trialHaematologica, 2015
- Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center StudyTransplantation and Cellular Therapy, 2011
- The EBMT risk scoreBone Marrow Transplantation, 2011
- Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?Journal of Clinical Oncology, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomesBlood, 2009
- Impacts of Pretransplant Comorbidities on Allogeneic Hematopoietic Cell Transplantation (HCT) OutcomesTransplantation and Cellular Therapy, 2009
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Chronic graft-versus-host syndrome in manThe American Journal of Medicine, 1980